Shares of Grifols SA - ADR - Level III (NASDAQ: GRFS) rose 2.80% Friday.

As of 11:56:50 est, Grifols SA - Level III sits at $12.88 and has risen $0.35 so far today.

Grifols SA - Level III has moved 15.82% over the last 30 days and has moved YTD 11.49% based on the prior day’s close.

The company expects its next earnings on 2022-07-28.

For technical charts, analysis, and more on Grifols SA - Level III visit the company profile.

About Grifols SA - ADR - Level III

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 100 countries. Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. In 2019, Grifols' economic impact in its core countries of operation was EUR 8.5 billion. The company also generated 148,000 jobs, including indirect and induced.

To get more information on Grifols SA - ADR - Level III and to follow the company's latest updates, you can visit the company's profile page here: Grifols SA - ADR - Level III's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold

The Best Laid Plans of Mice and Men — Part I

Bumble Beats First Quarter Estimates, Has Over 3 Million Paying Users

Squarespace Beats Revenue Estimates With Record Q1

BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million

How To Trade in a Bearish Market

AbbVie and Teva Weighing $5 Billion Opioid Lawsuit Settlement